MENU
CHRS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Coherus Oncology (CHRS) Ownership - Who owns Coherus Oncology?
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
333 Twin Dolphin Drive
Phone
+1 650 649-3530
Employees
306
Web
https://www.coherus.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
86.15M
P/E Ratio
1.68
Total Cash
82.41M
Projected Growth
N/A
Total Debt
269.93M
Revenue
272.25M
Risk (Beta)
0.62
Dividend Yield
N/A
Total Cash/Share
0.71
Total Debt/Equity
N/A
Revenue/Share
2.35 USD as % of share price
Fundamentals
CHRS
Capitalization
86.2M
P/E Ratio
1.68
Risk (Beta)
0.62
Dividend Yield
N/A
Total Cash
82.4M
Total Cash/Share
0.71
Total Debt
270M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
2.35%
Revenue
272M
ROE
N/A
Book Value
-183.47M
P/B Ratio
N/A
Cash Flow
N/A
Earnings
-1.15
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
12K
Current Ratio
1.22
Current Revenue Per Employee
34384.62
Dividends Per Share - Security
N/A
EBITDA
80.2M
Float
N/A
Float - Current
N/A
Gross Income Margin
65.09
Revenue To Assets
-23.08
Shares Held By Institutions
74.9M
Shares Outstanding - Current
116M
Total Liabilities
555M
Total Volume MTD
N/A
Value
-1
Gain YTD
-46.152
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
333 Twin Dolphin Drive
Phone
+1 650 649-3530
Employees
306
Web
https://www.coherus.com